Drugs / CDX-1307
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00648102 | Jan 2006 → May 2009 | breast cancer, colorectal cancer, malignant pancreatic neoplasm, ovarian cancer +1 | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00709462 | Mar 2004 → May 2010 | breast cancer, colorectal cancer, malignant pancreatic neoplasm, ovarian cancer +1 | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01094496 | Apr 2010 → Jul 2011 | urinary bladder cancer | Celldex Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDX-1307 | “CDX-1307 is an investigational drug that is being tested to see if it can stimulate the immune system” NCT00709462 ↗ |
| Modality | Vaccine | “a Mannose Receptor-Targeted hCG-β Vaccine” NCT00648102 ↗ |
| Route | Intravenous | “The study drug, CDX-1307, is given as an intravenous infusion” NCT00648102 ↗ |